The annual World Biosimilar Congress is the region's most targeted market place for biosimilar and biobetter stakeholders: an exhibition, a strategic keynote conference and real life case studies.
2016 not only saw the 4th Annual World Biosimilar Congress but it was a real inflection point for the industry. After a number of approvals in the US, the Biosimilar Industry is now finally ready to fulfil its promise and become a multi-billion dollar business providing real benefits to healthcare.
On the back of the approvals it is becoming a far more crowded and competitive landscape but getting a biosimilar to the patient still presents a number of challenges that the World Biosimilar Congress 2017 will look to address.
Across the two days, industry and thought-leading speakers from across the globe will come together to network and discuss the key issues on biosimilar drug development and healthcare uptake.
Key topics will include:
The Global R&D and Regulatory Landscape
Designing Biosimilar Development Programmes
Bioanalytics for Biosimilars
Characterisation and Comparison of Biosimilars to Originators
Extrapolation and Interchangeability
Pharmacovigilance in Biosimilars
Legal Considerations for Biosimilars
Biosimilar Uptake and Market Considerations
2016 was our biggest Congress to date and on the back of that we are expanding it for 2017 to include 2 tracks, one focusing on drug development and the other on market access.
We are excited to bring together representative from across the whole value chain who are working together to ensure that we are providing cost effective biologics for payers, prescribers and patients. I hope you can join us and I look forward to seeing you there.
Privacy statement »
Remember my details
Manage your email preferences »
You will be emailed the document as an attachment (1,810Kb in size)